The First 1000 Dendritic Cell Vaccinees

Cancer Investigation

Volumn 21, Issue 6, 2003, Pages 873-886

  Ridgway, Derry ^a  

^a Lineberry Associates   (United States)

Author keywords

Dendritic; Immunotherapy; Vaccine

Indexed keywords

ANTINUCLEAR ANTIBODY; CANCER VACCINE; PEPTIDE; RHEUMATOID FACTOR; THYROID ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ALOPECIA; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD TRANSFUSION REACTION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CELL FUSION; CELL MATURATION; CELL STIMULATION; CELLULAR IMMUNITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CRYOPRESERVATION; DENDRITIC CELL; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG SYNTHESIS; DYSPNEA; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAND; HEADACHE; HEMOLYSIS; HUMAN; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE; LEUKOCYTOSIS; LYMPHADENOPATHY; MEDICAL LITERATURE; MEDICAL SOCIETY; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PEER REVIEW; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; PSORIATIC ARTHRITIS; PUBLICATION; RASH; RIGOR; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR CELL; VACCINATION; VITILIGO;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 0346096827     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120025091     Document Type: Article

References (106)

1. Holtl, L.; Rieser, C.; Papesh, C.; Ramoner, R.; Herold, M.; Klocker, H.; Radmayr, C.; Stenzl, A.; Bartsch, G.; Thurner, M. Cellular and immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. 1999, 161, 777-782.
2. Steinman, R.M.; Dhodapkar, M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 2001, 94, 459-473.
3. Mukherji, B.; Chakraborty, N.G.; Yamasaki, S.; Okina, T.; Yamase, H.; Sporn, J.R.; Kurtzman, M.T.; Ergin, M.T.; Ozols, J.; Meehan, J.; Mauri, F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. 1995, 9, 8078-8082.
4. Toungouz, M.; Libin, M.; Bulte, F.; Faid, L.; Lehmann, F.; Duriau, D.; Laporte, M.; Gangji, D.; Bruyns, C.; Lambermont, M.; Goldman, M.; Velu, T. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J. Leukoc. Biol. 2001, 69, 937-943.
5. Desai, J.; Mitchell, P.; Lovelan, B.; Bardsley, B.; White, S.; Zhao, A.; Apostolopoulos, V.; Oslinski, C.; Xing, P.X.; Smith, C.; McDonald, C.; McKenzie, I. A phase I trial of dendritic cells pulsed with MUC1 peptide in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2002, 21, 15b (abstr).
6. Nair, S.K.; Morse, M.; Boczkowski, M.A.; Cumming, I.; Vasovic, L.; Gilboa, E.; Lyerly, K. Induction of tumor-specific cytotoxic t lymphycytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 2002, 35, 540-549.
7. Nishiyama, T.; Tachibana, M.; Horiguchi, Y.; Nakamura, K.; Ikeda, Y.; Takesako, K.; Murai, M. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin. Cancer Res. 2001, 7, 23-31.
8. Brossart, P.; Wirths, S.; Stuhler, G.; Reichardt, V.L.; Kanz, L.; Brugger, W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2001, 96, 3102-3108.
9. Morse, M.A.; Mosca, P.J.; Hobeika, A.; Clay, T.; Fisher, M.; Peter, St.M.; Williams, R.; Cumming, R.I.; Caron, D.; Lyerly, H.K. Immunotherapy with Flt3-ligand (Flt3L) mobilized dendritic cells (DC) loaded with carcinoembryonic antigen (CEA) peptide (CAP-1) in patients with metastatic malignancies expressing CEA. Proc. Am. Soc. Clin. Oncol. 2000, 19, 469a (abstr).
10. Vonderheide, R.H.; Domchek, S.M.; Hahn, W.C.; George, D.J.; Stephans, K.F.; Schultze, J.L.; Nadler, L.M. Vaccination of cancer patients against telomerase: a phase I study using peptide-pulsed dendritic cells. Blood 2001, 98, 508a (abstr).
11. Nussey, F.E.; Downing, I.; Waterfall, M.; Campbell, J.; Hunter, N.R.; Parker, J.; Innes, J.; Samuel, K.; Cook, G.; Turner, M.L.; Leonard, R.C. A phase one trial of autologous MUC-1 pulsed dendritic cells for the treatment of patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2000, 19, 476a (abstr).
12. Clay, T.M.; Hobeika, A.C.; Colling, K.; Ghanayem, M.; Heck, R.; Peplinski, S.; Peter, St.M.; Cheever, M.A.; Grabstein, K.; Mosca, P.J.; Morse, M.A.; Lyerly, K. Comparison of the immunologic responses in metastatic breast cancer patients vaccinated with either non-matured or matured dendritic cells loaded with HER-2/neu intracellular domain (ICD) protein. Proc. Am. Assoc. Cancer Res. 2002, 43, 89 (abstr).
13. Aoyama, T.; Fujii, Y.; Hasumi, K.; Yamaguchi, S.; Terai, M.; Yasuda, R.; Arai, T.; Nathan, F.E.; Mastrangelo, M.J.; Sato, T. Active specific immunotherapy with tumor-antigen pulsed dendritic cells (DC) and CD-40 ligand expressing activated T cells (AT). Proc. Am. Soc. Clin. Oncol. 2001, 20, 221b (abstr).
14. Cajal, R.; Maordomo, J.I.; Yubero, A.; Lasierra, P.; Isla, D.; Blasco, C.; Fuertes, M.A.; Palomera, R.; Sousa, R.; Guermes, A.; Escudero, P.; Saenz, A.; Garcia, M.; Larrad, L.; Tres, A. Immunological and clinical effects of immunotherapy with dendritic cells pulsed with tumor lysates in patients with advanced cancer. A pilot trial. Proc. Am. Soc. Clin. Oncol. 2000, 19, 454a (abstr).
15. Chang, A.E.; Redman, B.G.; Whitfield, J.R.; Nickoloff, B.J.; Braun, T.M. ; Lee, P.P.; Geiger, J.D.; Mule, J.J. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 2002, 8, 1021-1032.
16. Avigan, D.; Gong, J.; Uhl, L.; Wu, Z.; Vasir, D.; Smith, T.; Borges, V.; Atkins, M.; Stone, C.; Giallombardo, N.; Schadt, K.; Tetreault, J.C.; Kufe, D. Dendritic cell tumor fusions as a novel tumor vaccine: a phase I trial for patients with metastatic breast cancer. Blood 2001, 98, 14a (abstr).
17. Morse, M.A.; Coleman, R.E.; Akabani, G.; Niehaus, N.; Coleman, D.; Lyerly, H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999, 59, 56-58.
18. Fong, L.; Hou, Y.; Benike, C.; Yuen, A.; Fisher, G.A.; Davis, M.M.; Engleman, E.C. Vaccination with increasing doses of Flt3 ligand expanded dendritic cells loaded with a carcinoembyonic antigen derived epitope. Proc. Am. Assoc. Cancer Res. 2002, 43, 143-144 (abstr).
19. Westermann, J.; Kopp, J.; Korner, I.; Dohner, C.; Dohner, H.; Mohm, J.; Ehninger, G.; Richter, G.; Dorken, B.; Pezzutto, A. Dendritic cells for vaccination in BCR/ABL-positive chronic myeloid leukemia. Blood 2000, 96, 144a (abstr).
20. Westermann, J.; Kopp, J.; Korner, I.; Dohner, C.; Dohner, H.; Dorken, B. ; Pezzutto, A. Dendritic cells as vaccine in BCR/ABL-positive chronic myelogenous leukemia: a phase I study. Blood 2001, 98, 350a (abstr).
21. Ossenkeppele, G.J.; Stam, A.G.M.; Westers, T.M.; de Gruijl, T.D.; van de Loosdrecht, A.A.; Scheper, R.J. Pilot study on active specific immunization with autologous in vitro cultured leukemic dendritic cells in chronic phase CML. Blood 2001, 98, 265b (abstr).
22. Fong, L.; Hou, Y.; Benike, C.; Wu, L.; Engleman, E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Assoc. Sci. 2001, 98, 8809-8814.
23. Weihrauch, M.R.; Geisen, C.; Jurkeiwicz, E.; Wittig, B.; Diehl, V.; Wolf, J.; Bohlen, H. Combined immuno-/chemotherapy with CAP-1 pulsed dendritic cells or CPG-ODN in patients with primary metastatic colon cancer. Blood 2000, 96, 618a (abstr).
24. Sandanaga, N.; Nagashima, H.; Mashino, K.; Tahara, K.; Yamaguchi, H.; Ohta, M.; Fujii, T.; Tanaka, F.; Inoue, H.; Takesako, K.; Akiyoshi, T.; Mori, M. Dendritic cell vaccination with mage peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 2001, 7, 2277-2284.
25. Tsunoda, T.; Tanimura, H.; Tanaka, H.; Matsuda, K.; Umano, Y.; Shono, Y. ; Iwahashi, M.; Yamaue, H.; Takesako, K.; Ideno, M.; Nukaya, I. Cytotoxic peptide can elicit HLA-restricted CEA specific CTL from colorectal cancer patients in vivo-development of colorectal cancer vaccine. Proc. Am. Assoc. Cancer Res. 1999, 40, 310 (abstr).
26. Itoh, T.; Ueda, Y.; Kawashima, I.; Nukaya, I.; Fujiwara, H.; Fuji, N.; Yamashita, T.; Yoshimura, T.; Okugawa, K.; Iwasaki, T.; Ideno, M.; Takesako, K. ; Mitsihashi, M.; Orita, K.; Yamagishi, H. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol. Immunother. 2002, 51, 99-106.
27. Rains, N.; Cannan, R.J.; Chen, W.; Stubbs, R.S. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001, 48, 347-351.
28. Abe, T.; Takahashi, M.; Aichun, L.; Narita, T.; Furukawa, T.; Toba, K.; Aizawa, Y. Application of dendritic cells pulsed with SART-1 peptide to patients with esophageal cancer. Blood 2000, 96, 38b (abstr).
29. Takahashi, M.; Narita, M.; Abe, T.; Liu, A.; Kanda, T.; Kaifu, T.; Yamanaka, R.; Furukawa, T.; Toba, K.; Hatakeyama, K.; Tanaka, R.; Aizawa, Y. Anti-tumor immunotherapy using dendritic cells pulsed with tumor peptides or acid-eluted tumor antigens. Blood 2001, 98, 40b (abstr).
30. Tanigawa, K.; Shimizu, K.; Aruga, A.; Takasaki, K. A clinical trial of intratumoral injection of dendritic cells to GI cancers. Proc. Am. Assoc. Cancer Res. 2001, 42, 27 (abstr).
31. Yu, J.S.; Wheeler, C.J.; Zeltzer, P.M.; Ying, H.; Finger, D.N.; Lee, P.K.; Yong, W.H.; Incardona, F.; Thompson, R.C.; Riedinger, M.S.; Zhang, W.; Prins, R.M.; Black, K.L. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001, 61, 842-847.
32. Chuhjo, T.; Wang, H.; Kondo, Y.; Uchiyama, N.; Hayashi, Y.; Fujii, S.; Yamashita, S.; Nakao, S. Dendritic cell therapy of glioblastoma: evidence of antitumor immune response in vivo. Blood 2000, 96, 617a (abstr).
33. Yu, J.S.; Wheeler, C.J.; Zeltzer, P.M.; Ying, H.; Lee, P.K.; Incardona, F.; Yong, W.H.; Thompson, R.C.; Riedinger, M.S.; Black, K.L. Dendritic cell immunotherapy for patients with glioblastoma multiforme and anaplastic astrocytoma. Proc. Am. Assoc. Cancer Res. 2001, 42, 274-275 (abstr).
34. Liau, L.M.; Salgaller, M.L.; Kiertscher, S.M.; Cloughesy, T.F.; Mischel, P.S.; Martin, N.A.; Becker, D.P.; Roth, M.D. Dendritic cell vaccine presenting eluted antigens for treatment of patients with glioblastoma multiforme: interim phase I trial results of DCVax™-Brain(elu). Proc. Am. Assoc. Cancer Res. 2002, 43, LB130 (abstr).
35. Kikuchi, T.; Akasaki, Y.; Irie, M.; Homma, S.; Abe, T.; Ohno, T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 2001, 50, 337-344.
36. Park, T.W.; Hernando, J.J.; Kuebler, K.; Bauknecht, T. A phase I study of vaccination with tumor cell lysate-pulsed dendritic cells in patients with advanced gynecologic cancers. Proc. Am. Soc. Clin. Oncol. 2001, 20, 269a (abstr).
37. Stift, A.; Dubsky, P.; Friedt, J.P.; Bachleitner, T.; Schueller, G.; Tadlbauer, K.; Jakesz, R.; Gnant, M.F. A pilot study for a phase I trial of active immunotherapy using tumor lysate pulsed autologous dendritic cells in patients with incurable malignancies. Proc. Am. Soc. Clin. Oncol. 2000, 19, 464a (abstr).
38. Midgley, R.; Kerr, D.J.; Mirza, N.; Milner, A.; Hodgkin, E.; Barker, S.; Adams, D. A phase II dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC). Proc. Am. Soc. Clin. Oncol. 2002, 21, 23b (abstr).
39. Hsu, F.J.; Benike, C.; Fagnoni, F.; Liles, T.M.; Czerwinski, D.; Taidi, B.; Engleman, E.G.; Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996, 2, 52-58.
40. Hsu, F.J.; Komarovskaya, M.; Song, B.; Doyon, A.G. Active immunotherapy of patients with lymphoma with sequential dendritic cell and protein/adjuvant idiotype vaccines. Blood 1999, 94, 386a (abstr).
41. Hsu, F.J.; Komarovskaya, M.; Song, B.; Doyon, A.G. A clinical trial of sequential dendritic cell and protein/adjuvant idiotype vaccines in patients with follicular lymphomas. Blood 2001, 98, 466a-467a (abstr).
42. Timmerman, J.M.; Czerwinski, D.K.; Davis, T.A.; Hsu, F.J.; Benike, C.; Hao, Z.M.; Taidi, B.; Ranjani, R.; Caspar, C.B.; Okada, C.Y.; van Beckhoven, A. ; Liles, T.M.; Engleman, E.G.; Levy, R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immunological responses in 35 patients. Blood 2002, 99, 1517-1526.
43. Fay, J.; Palucka, K.; Dhodapkar, M.; Burkeholder, S.; Taquet, N.; Rolland, A.; Bhardwaj, N.; Pineiro, L.; Stone, M.; Steinman, R.; Banchereau, J. Dendritic cell immunotherapy of metastatic melanoma using CD34+ hematopoietic progenitor-derived dendritic cells (CD34-DC) induced immune responses to melanoma antigen and resulted in clinical regression of metastatic disease. Blood 2000, 96, 807a (abstr).
44. Lau, R.; Kuniyoshi, J.; Jeffery, G.; Marty, V.; Snively, J.; Groshen, S. ; Weber, J. Phase II trial of CD40 ligand treated peptide-pulsed dendritic cells plus IL-2 in advanced melanoma. Proc. Am. Soc. Clin. Oncol. 2001, 20, 264a (abstr).
45. Leong, S.P.L.; Zhou, Y.M.; Peng, M.; Nelken, P.; Chang, J.W.C.; Vaquerano, J.E.; Hyun, W.C. Immunotherapy of melanoma with dendritic cells pulsed with autologous melanoma apoptotic bodies. Proc. Am. Soc. Clin. Oncol. 2001, 20, 268a (abstr).
46. Lotze, M.T.; Shurin, M.; Esche, C.; Tahara, H.; Storkus, W.; Kirkwood, J.M.; Whiteside, T.L.; Elder, E.M.; Okada, H.; Robbins, P. Interluekin-2: developing additional cytokine gene therapies using fibroblasts or dendrific cells to enhance tumor immunity. Cancer J. Sci. Am. 2000, 6(Suppl 1), S61-S66.
47. Mackensen, A.; Herbst, B.; Chen, J.L.; Kohler, G.; Noppen, C.; Herr, W.; Spagnoli, G.C.; Cerundolo, V.; Lindemann, A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 2000, 86, 385-392.
48. Nestle, F.O.; Alijagic, S.; Gilliet, M.; Sun, Y.; Drrabbe, S.; Dummer, R.; Burg, G.; Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cels. Nat. Med. 1998, 4, 328-332.
49. Nestle, F.O. Dendritic cell vaccination for cancer therapy. Oncogene 2000, 19, 6673-6679.
50. Panelli, M.C.; Wunderlich, J.; Jeffries, J.; Wang, E.; Mixon, A.; Rosenberg, S.A.; Marincola, F.M. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother. 2000, 23, 487-498.
51. Ribas, A.; Butterfield, L.H.; Vu, H.T.; Amarnani, S.; Dissette, V.N.; Oseguera, D.K.; McBride, W.H.; Glaspy, J.A.; Economos, J.S. Dose and route of dendritic cell (DC)-based vaccination for further human testing: a phase I trial. Proc. Am. Soc. Clin. Oncol. 2001, 20, 268a (abstr).
52. Thurner, B.; Haendle, I.; Roder, C.; Dieckmann, D.; Keikavoussi, P.; Jonuleit, H.; Bender, A.; Maczek, C.; Schreiner, D.; von den Driesch, P.; Brocker, E.B.; Steinman, R.M.; Enk, A.; Kampgen, E.; Schuler, G. Vaccination with mage-3A1, peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999, 190, 1669-1678.
53. Schuler-Thurner, B.; Dieckmann, D.; Keikavoussi, P.; Bender, A.; Maczek, C.; Jonuleit, H.; Roder, C.; Haendle, I.; Leisgang, W.; Dunbar, R.; Cerundolo, V.; von Den Driesch, P.; Knop, J.; Brocker, E.B.; Enk, A.; Kampgen, E.; Schuler, G. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1 + melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 2000, 154, 3492-3496.
54. Banchereau, J.; Palucka, A.K.; Dhodapkar, M.; Burkeholder, S.; Taquet, N.; Rolland, A.; Taquet, S.; Coquery, S.; Wittkowski, K.M.; Bhardwaj, N.; Pineiro, L.; Steinman, R.; Fay, J. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 2001, 61, 6451-6458.
55. Jonuleit, H.; Giesecke-Tuettenberg, A.; Tuting, T.; Thurner-Schuler, B.; Stuge, T.B.; Paragnik, L.; Kandemir, A.; Lee, P.P.; Schuler, G.; Knop, J.; Enk, A.H. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 2001, 93, 243-251.
56. Gajewski, T.F.; Fallarino, F.; Ashikari, A.; Sherman, M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 2001, 3(Suppl 3), 895s-901s.
57. Riccobon, A.; Ridolfi, R.; De Paola, F.; Barzanti, F.; Mosconi, G.; Ortolani, F.; Stefanelli, M.; Ibrahim, T.; Ridolfi, L.; Fabbri, M.; Flamini, E. ; Amadori, D. Vaccination with dendritic cells (DC) pulsed with heat shock proteins (HSP) or lysate from autologous tumor in advanced melanoma patients. Proc. Am. Soc. Clin. Oncol. 2000, 19, 469a (abstr).
58. Linette, G.; Jonasch, E.; Longerich, S.; Yang, D.S.; Webb, I.; Szczepiorkowski, Z.; Cheung, A.; Haluska, F. Phase I study of therapy with peptide-pulsed autologous dendritic cells for advanced melanoma. Proc. Am. Soc. Clin. Oncol. 2000, 19, 467a (abstr).
59. Faries, M.B.; Bedrosian, I.; Xu, S.; Kohl, K.; Nissenbaum, H.; Cohen, P. ; Czerniecki, B.J. Effective immunization to melanoma antigens by intranodal injection of mature, CD83+ dendritic cells. Proc. Am. Soc. Clin. Oncol. 2000, 19, 453a (abstr).
60. Punt, C.J.A.; de Vries, I.J.M.; Eggert, A.A.O.; Schreurs, M.W.J.; Scharenborg, N.H.; Verstratenm, H.G.G.; Ruiter, D.J.; Boerman, O.C.; Oyen, W.J.G.; Adema, G.J.; Figdor, C.G. Immunization with dendritic cells (DC) pulsed with synthetic peptides, murine and clinical studies. Proc. Am. Assoc. Cancer Res. 1999, 40, 312 (abstr).
61. Schuler-Thurner, B.; Schultz, E.S.; Berger, T.G.; Weinlich, G.; Ebner, S.; Woerl, P.; Bender, P.; Feuerstein, B.; Fritsch, P.O.; Romani, N.; Schuler, G. Rapid induction of tumor-specific type I T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. Exp. Med. 2002, 19, 1279-1288.
62. Nagayama, H.; Sato, K.; Enomoto, M.; Uchimaru, K.; Saida, T.; Shimada, S.; Kawakami, Y.; Asano, S.; Yamashita, N.; Takahashi, T.A. Phase I clinical study of autologous monocyte-derived dendritic cell therapy for stage IV malignant melanoma patients in Japan. Blood 2000, 96, 323b (abstr).
63. Morishita, M.; Oyaizu, N.; Uchimaru, K.; Sato, K.; Nagayama, H.; Inzazwa, T.; Nakoako, T.; Akagawa, E.; Shimada, S.; Kawakami, Y.; Saida, T.; Yamamoto, A.; Tani, K.; Asana, S.; Takahashi, T.; Yamashita, N. Dendritic cell therapy for stage IV melanoma: two cases of multiple tumor necrosis. Blood 2001, 98, 18a-19a (abstr).
64. Chakraborty, N.G.; Sporn, J.R.; Tortora, A.F.; Kurtzman, S.H.; Yamase, H.; Ergin, M.T.; Mukherji, B. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol. Immunother. 1998, 47, 58-64.
65. Bercovici, N.; Massicard, S.; Baron, V.; Pauillac, F.; Hamon, I.; Agrawal, S.; Goxe, B.; Latour, N.; Duffour, M.-T.; Boccaccio, C.; Boyer, A.; Nardin, A.; Chauvet, I.; Prigent, D.; Heshmati, F.; Duriau, D.; Vereecken, P.; Bruyns, C.; Lehmann, F.; Velu, T.; Romet-Lemonne, J.-L.; Abastado, J.-P.; Salcedo, M. Immunization with dendritic cells generated in the presence of GM-CSF and IL-13 loaded with an allogeneic melanoma cell lysate: a phase I study in patients with metastatic melanoma. Proc. Am. Assoc. Cancer Res. 2002, 43, 558-559 (abstr).
66. Chang, J.W.; Hsieh, J.-J.; Chen, J.-S.; Yang, T.-S.; Wang, C.-H.; Chiang, H.-F.; Lo, Y.-F.; Chang, C.-J.; Yang, C.-S.; Yeh, J.-T.; Chang, T.-C.; Chen, Y.-R.; Liao, S.-K.; Gung, C. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-treated melanoma apoptotic cells for patients with malignant melanoma. Proc. Am. Soc. Clin. Oncol. 2002, 21, 3b (abstr).
67. Wallack, M.K.; Kim, E.M.; Stavropoulos, C.I.; Mancke, B.; Sivanandham, M. A pilot trial with a vaccinia virus-augmented melanoma lysate-pulsed dendritic cell vaccine (DC-Melvac) for patients with advanced melanoma. Proc. Am. Soc. Clin. Oncol. 2002, 21, 240b (abstr).
68. Tozer, R.G.; McCulloch, P.B.; Dent, P.; Levine, M.; Ross, C.; Scheid, E. ; Gauldie, J.; Kowalski, Y.; Wan, B.; Roberts, R. Vaccination with autologous CD34+ derived dendritic cells transduced with an adenovirus expressing human gp100 in patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol. 2002, 21, 352a (abstr).
69. Haluska, F.G.; Linette, G.P.; Jonasch, E.; Hodi, S.; Longerich, S.; Yang, S.; Webb, I.; Stowell, C.; Kaplan, J.; Roberts, B.; Goldberg, M. Immunologic gene therapy of melanoma: phase I study of therapy with autologous dendritic cells transduced with recombinant adenoviruses encoding melanoma antigens. Proc. Am. Soc. Clin. Oncol. 2000, 19, 453a (abstr).
70. Cull, G.; Durant, L.; Haynes, A.; Russell, N. Generation of idiotype-specific immune responses following vaccination with autologous paraprotein pulsed dendritic cells in myeloma. Blood 2000, 92, 275b (abstr).
71. Lacy, M.Q.; Wettstein, P.; Gertz, M.A.; Gastineau, D.A.; Greipp, P.R.; Fonseca, R.; Lust, J.; Witzig, T.; Rajkumar, S.V.; Valone, F.; Kyle, R.A. Dendritic cell-based idiotype vaccination in post transplant multiple myeloma. Blood 2000, 96, 374a (abstr).
72. Lim, S.H.; Bailey-Wood, R. Idiotype protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 1999, 83, 215-222.
73. Liso, A.; Stockerl-Goldstein, K.E.; Aufferman, S.; Benike, C.J.; Reichardt, V.; van Beckhoven, A.; Rajapaksa, R.; Engleman, E.G.; Blume, K.G.; Levy, R. Idiotype vaccination using dendritic cells afer autologous peripheral blood progenitor cell transplantation for multiple myeloma. Blood 1999, 94, 715a (abstr).
74. MacKenzie, M.; Peshwa, M.V.; Wun, T.; Wolf, J.; Mason, J.; Caggiano, V.; Redfern, C.; Strang, G.; Valone, F. Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge). Blood 2000, 96, 166a (abstr).
75. Titzer, S.; Christensen, O.; Manzke, O.; Tesch, H.; Wolf, J.; Emmerich, B.; Carsten, C.; Diehl, V.; Bohlen, H. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Brit. J. Haematol. 2000, 108, 805-816.
76. Maecker, H.T.; Auffermann-Gretzinger, S.; Nomura, L.E.; Liso, A.; Czerwinski, D.K.; Levy, R. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. Clin. Cancer Res. 2001, 7(Suppl 3), 902s-908s.
77. Reichardt, V.L.; Wirths, S.; Milazzo, C.; Brossart, P.; Stuhler, G.; Einsele, H.; Brugger, W.; Kanz, L. Specific immunotherapy of multiple myeloma patients using idiotype pulsed serum free generated dendritic cells. Blood 2000, 96, 63a (abstr).
78. Reichardt, V.L.; Milazzo, C.; Brugger, W.; Einsele, H.; Kanz, L.; Brossart, P. Specific immunotherapy of multiple myeloma patients using idiotype pulsed serum free generated dendritic cells. Blood 2001, 98, 378a-379a (abstr).
79. Wen, Y.J.; Ling, M.; Bailey-Wood, R.; Lim, S.H. Idiotype protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 1998, 4, 957-962.
80. Ishisaka, T.; Nevin, B.; Valone, F.H.; Kothari, S.S.; Peshwa, M.V. Comparison of cryopreserved versus fresh formulation of idiotype-loaded autologous dendritic cell vaccine. Blood 2001, 98, 309b (abstr).
81. Yi, Q.; Desikan, R.; Barlogie, B.; Munsh, N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Blood 2001, 98, 374a (abstr).
82. Lacy, M.; Wettstein, P.; Gertz, M.A.; Gastineau, D.A.; Greipp, P.R.; Fonseca, R.; Dispenzieri, A.; Lust, J.; Witzig, T.; Rajkumar, S.V.; Geyer, S.; Valone, F.; Kyle, R.A. Postautologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (dendritic) cells (APC8020). Proc. Am. Soc. Clin. Oncol. 2002, 21, 31a (abstr).
83. Geiger, J.; Hutchinson, R.; Hohenkirk, L.F.; McKenna, E.; Chang, A.; Mule, J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000, 356, 1163-1165.
84. Geiger, J.D.; Hutchinson, R.J.; Hohenkirk, L.F.; McKenna, E.A.; Yanik, G.A.; Levine, J.E.; Chang, A.E.; Braun, T.M.; Mule, J.J. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001, 61, 8513-8519.
85. Schott, M.; Feldkamp, J.; Lettmann, M.; Simon, D.; Scherbaum, W.A.; Seissler, J. Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. Clin. Endocrin. 2001, 55, 271-277.
86. Gjertsen, M.K.; Bakka, A.; Breivik, J.; Saeterdal, I.; Gedde-Dahl, T., 3rd; Stokke, K.T.; Solheim, B.G.; Egge, T.S.; Soreide, O.; Thorsby, E.; Gaudernack, G. Ex vivo peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int. J. Cancer 1996, 65, 450-453.
87. Schott, M.; Feldkamp, J.; Schattenberg, D.; Krueger, T.; Dotzenrath, C.; Seissler, J.; Scherbaum, W.A. Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur. J. Endocrinol. 2000, 142, 300-306.
88. Burch, P.A.; Breen, J.K.; Buckner, J.C.; Gastineau, D.A.; Kaur, J.A.; Padley, D.J.; Peshwa, M.V.; Pitot, H.C.; Richardson, R.L.; Smits, B.J.; Sopapan, P.; Strang, G.; Valone, F.H.; Vuk-Pavlovic, S. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 2000, 6, 2175-2182.
89. Fong, L.; Brockstedt, D.; Benike, C.; Wu, L.; Engleman, E.G. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 2001, 166, 4254-4259.
90. Fong, L.; Brockstedt, D.; Benike, C.; Breen, J.K.; Strang, G.; Ruegg, C.L.; Engleman, E.G. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol. 2001, 167, 7150-7156.
91. Frohlich, M.W.; Small, E.J.; Bok, R.A.; Gulla, S.P.; Valone, F.H.; Harris, K.A.; Reese, D.M. Immunotherapy with prostatic acid phosphatase-loaded dendritic cells (PROVENGE) in prostate cancer patients with serologic progression after definitive local therapy. Proc. Am. Soc. Clin. Oncol. 2001, 20, 188a (abstr).
92. Small, E.J.; Fratesu, O.; Reese, D.M.; Strang, G.; Laus, R.; Peshwa, M.V.; Valone, F.H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 2000, 18, 3894-3903.
93. Tjoa, B.A.; Elgamal, A.A.; Murphy, G.P. Vaccine therapy for prostate cancer. Urol. Clin. North Am. 1999, 26, 365-374.
94. Shankar, G.; Kelley, H.; Lodge, A.; Boynton, A.; Papandreou, C.; Logothetis, C.; Elgamal, A.-A. Monitoring immune responses of prostate cancer patients vaccinated with prostate-specific membrane antigen (PSMA) protein-loaded dendritic cells (DC) in a phase I/II clinical trial. Proc. Am. Assoc. Cancer Res. 2001, 42, 26-27 (abstr).
95. Shankar, G.; Kelley, H.; Samadzadeh, L.; Lodge, A.; Boynton, A.; Papandreou, C.; Logothetis, C.; Belldegrun, A.; Elgamal, A. Induction of tumor-specific immune responses in hormone-refractory prostate cancer patients treated with DCVax™ Prostate in a phase I/II clinical trial. Proc. Am. Assoc. Cancer Res. 2002, 43, 144 (abstr).
96. Assikis, V.J.; Elgamal, A.-A.; Tu, S.-M.; Daliani, D.; Pagliaro, L.; Logothetis, C.; Papandreou, C. Immunotherapy for androgen independent prostate cancer: results of a phase I trial with a tumor vaccine of autologous dendritic cells loaded with r-PSMA (DCVax™-Prostate). Proc. Am. Assoc. Cancer Res. 2002, 43, 676 (abstr).
97. Takaue, Y.; Tanosaki, R.; Tobisu, K.; Kakizoe, T.; Mizunuma, Y.; Kawai, H. Antigen-pulsed dendritic cell therapy for the treatment of hormone-refractory prostate cancer: a phase I trial of APC8015. Proc. Am. Soc. Clin. Oncol. 2002, 21, 18b (abstr).
98. Mansi, J.L.; Pandha, H.S.; John, J.; Hutchinson, J.; Kristeleit, H.; Dalgleish, A. Dendritic cell immunotherapy for metastatic prostate cancer using cryopreserved dendritic cells pulsed with allogeneic tumour lysate: a phase I/ II trial. Proc. Am. Soc. Clin. Oncol. 2002, 21, 17b (abstr).
99. Vieweg, J.W.; Coleman, D.; Maurice, M.; Yancey, D.; Dahm, P.; Naoe, M.; Gilboa, E.; Heiser, A. Immunotherapy of prostate cancer using dendritic cells transfected with PSA RNA: results of a phase I trial. Proc. Am. Soc. Clin. Oncol. 2001, 20, 251a (abstr).
100. Heiser, A.; Coleman, D.; Dannull, J.; Yancey, D.; Maurice, M.A.; Lallas, C.D.; Dahm, P.; Niedzwiecki, D.; Gilboa, E.; Vieweg, J. Autologous dendritic cells transfected with prostate specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 2002, 109, 409-417.
101. Heiser, A.; Su, Z.; Dannull, J.; Coleman, D.; Yancey, D.; Maurice, M.; Lallas, C.; Dahm, P.; Niedzwiecki, D.; Gilboa, E.; Vieweg, J.W. Phase I clinical trial using dendritic cells transfected with PSA RNA for immunotherapy of prostate cancer patients. Proc. Am. Assoc. Cancer Res. 2002, 43, 976 (abstr).
102. Hinkel, A.; Gitlitz, B.; Mulders, P.; Moldawer, N.; Tso, C.; Kaboo, R.; Belldegrun, A.; Figlin, R. Dendritic cell (DC) therapy for metastatic renal cell carcinoma (mRCC)-a translational phase I clinical trial. Proc. Am. Soc. Clin. Oncol. 1998, 17, 432a (abstr).
103. Marten, A.; Renoth, S.; Heinicke, T.; von Lilienfeld-Toal, M.; Schmidt-Wolf, I.G.H. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a first clinical phase I/II trial in patients with metastatic renal cell carcinoma. Blood 2001, 98, 40a (abstr).
104. Kugler, A.; Stuhler, G.; Walden, P.; Zoller, G.; Zobywalski, A.; Brossart, P.; Trefzer, U.; Ullrich, S.; Muller, C.A.; Becker, V.; Gross, A.J.; Hemmerlein, B.; Kanz, L.; Muller, G.A.; Ringert, R.H. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 2000, 6, 332-336.
105. Schott, M.; Seissler, J.; Lettmann, M.; Fouxon, V.; Scherbaum, W.A.; Feldkamp, J. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab. 2001, 86, 4965-4969.
106. Schellhammer, P.; Small, E.J.; Higano, C.S.; Neumunaitis, J.; Peshwa, M. ; Jones, L.; Strang, G.; Valone, F.H. Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for hormone refractory prostate cancer: a phase III randomized, double blind, placebo controlled trial. Proc. Am. Soc. Clin. Oncol. 2002, 21, 183a (abstr).